Panel Tells the NIH Story - Past, Present and Future - United For Medical Research
UMR urges bipartisan progress on Labor-HHS funding bill. View the statement here.
A new episode of the Amazing Things Podcast is now available! View the episode here.
Learn about NIH’s Role in Sustaining the U.S. Economy. View the latest report here.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Panel Tells the NIH Story — Past, Present and Future

June 22, 2009

A strong crowd of Members of Congress, Hill staff, reporters and NIH/medical research supporters filled the Congressional Budget Committee hearing room on Capitol Hill today to hear UMR’s panel discussion about the need and benefits of steady increases in NIH funding, over time.

Michelle McMurry, MD, PhD, of the Aspen Institute Speaks about the Promise of Pharmacogenomics

Speakers touched on the needs of scientific research including the long-term investment that science requires to deliver real benefits to society. And they discussed the passion and comittment of young scientists – who are those most likely to bring forward groundbreaking new discoveries – but who most often remain unfunded.

The discussion also touched upon the immense opportunities and new demands that arise out of $10bn in American Recovery and Reinvestment Act funding for NIH.

Dr. Valle, MD, Professor & Director of Genetic Medicine at Johns Hopkins Speaks About Opportunities and Demands of ARRA Funding

Finally, panelists gave us a glimpse into the future – speaking about some of the most promising areas of life sciences research – including pharmacogenomics and new channels into cancer research that will lead to significant new treatments.

A transcript, full video and more info about the event will be available soon.

Kacy Redd, PhD and APLU Policy Research Associate and Jeff Liberman, host of Discovery Channel’s Time Warp
Dr. Len Lichtenfeld, MD, MACP Deputy Chief Medical Officer, American Cancer Society discussed long-term investments in life sciences and the potential for newly-identified channels in cancer research.